The purpose of this study is to evaluate whether Rebamipide facilitate the healing of inflamed mucosa as an adjuvant regimen in erosive reflux esophagitis (ERE).
Full Title of Study: “A Multicenter, Randomized, Double-blinded, Placebo-controlled Pilot Study to Evaluate the Efficacy and Safety of Rebamipide as an Adjuvant Regimen to Heal erosIve Reflux Esophagitis (REPAIR)”
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
- Masking: Double (Participant, Investigator)
- Study Primary Completion Date: January 2016
1. To evaluate whether Rebamipide facilitate the healing of inflamed mucosa as an adjuvant regimen in erosive reflux esophagitis patients 2. To evaluate the safety of rebamipide as an adjuvant regimen in erosive reflux esophagitis (ERE)
- Drug: Lansoprazole
- Oral administration of Lanston® (lansoprazole) 30 mg, 1 capsule, PO, qd, 30 min before breakfast
- Drug: Rebamipide
- Oral administration of Mucosta (rebamipide) 100 mg, 1 tablet, PO, tid, 30 minutes before breakfast, lunch, and dinner
- Drug: Rebamipide-placebo
- Oral administration of Mucosta®-placebo, 1 tablet, PO, tid, 30 minutes before breakfast, lunch and dinner
Arms, Groups and Cohorts
- Experimental: Study Group
- Lanston® (lansoprazole) 30 mg, 1 capsule, PO, qd, 30 min before breakfast Mucosta® (rebamipide) 100 mg, 1 tablet, PO, tid, 30 minutes before breakfast, lunch and dinner
- Placebo Comparator: Control Group
- Lanston® (lansoprazole) 30 mg, 1 capsule, PO, qd, 30 min before breakfast Mucosta®-placebo (rebamipide-placebo), 1 tablet, PO, tid, 30 minutes before breakfast, lunch and dinner
Clinical Trial Outcome Measures
- Endoscopic healing rate
- Time Frame: 4 weeks
- The ratio of the endoscopically completely healed (normal or minimal change) patients per groups
- Histologic change
- Time Frame: 4 weeks
- Histologic change defined with Hematoxylin and eosin (H&E) stain
- Change in inflammatory cytokines
- Time Frame: 4 weeks
- Change in the tissue level of Platelet activating factor (PAF) and Interleukin-8 (IL-8)
- Time to complete symptom relief
- Time Frame: every 2 week, up to 4 week
- Interval between inital medication and the first time of symptom relief judged by subject’s diary
- Overall symptom relief
- Time Frame: every 2 week, up to 4 week
- The proportion of relieved subjects at the end of treatment
- Adverse events profile
- Time Frame: every 2 week, up to 4week
- patient’s symptoms, physical findings, abnormal laboratory values, vital signs, and ECG findings
Participating in This Clinical Trial
1. Male/female patients aged 20 to 70 at the time of writing an informed consent. 2. Subjects who were diagnosed with Erosive Reflux Esophagitis (ERE) using Los Angeles (LA) classification grade A~D, confirmed by endoscopy. 3. The subjects regardless of presence of ERE symptom (i.e., symptomatic ERE or asymptomatic ERE). For symptomatic ERE, the subject must have one or more symptoms of the followings: acid regurgitation, heartburn, epigastric pain, cough, hoarseness, globus pharyngis, atypical chest pain. 4. Subjects who have consented to participate in this clinical study by signing an informed consent form. Exclusion Criteria:
1. Patients with known hypersensitivity to any component of Lanston® and/or Mucosta® formulations. 2. Other concurrent organic upper gastroesophageal disease in endoscopy (i.e., drug-induced esophagitis, viral esophagitis, Mallory-Weiss syndrome, peptic ulcer disease, malignancies) and patients who was diagnosed with Barrett's esophagus. 3. History of abdominal surgery that can affect gastrointestinal motility (except appendectomy and hysterectomy). 4. History of upper gastrointestinal bleeding or obstruction. 5. Patients administrated with any drugs that can affect the efficacy of study regimen (proton pump inhibitors, revaprazan, prokinetics, H2-blockers, etc.) within 2 weeks (however, 4 weeks for PPIs) prior to enrollment and/or those who are required of NSAIDs, anti-coagulants, anti-cholinergics, prostaglandin E, corticosteroids, and anti-depressants treatment during the study period. 6. History of pancreatobiliary disease (except asymptomatic gallbladder stone), inflammatory bowel disease, cirrhotic liver disease, chronic kidney disease. 7. Pregnant, nursing, and childbearing potential women who is unwilling to effective contraception; for example, oral contraceptives, hormonal methods, placement of an intrauterine device (IUD) or intrauterine system (IUS), barrier methods (i.e., condom or occlusive cap with spermicidal foam/gel/film/cream/suppository), male sterilization, and true abstinence. 8. History of psychological disorder, alcoholics, and drug abuser. 9. Blood test results of hemoglobin (Hb) ≤ 10.0 g/dL, platelets ≤ 50,000 /µL, total WBCs ≤ 4,000/µL or ≥ 10,000/µL, and with serum test results showing the levels of AST, ALT, ALP, BUN, and creatinine exceeding twice the normal range of respective institution. 10. Patients who previously underwent another clinical survey within 4 weeks. 11. History of major medical disease that can affect general condition and other patients deemed not eligible for this study by investigators.
Gender Eligibility: All
Minimum Age: 20 Years
Maximum Age: 70 Years
Are Healthy Volunteers Accepted: No
- Lead Sponsor
- YongChan Lee
- Otsuka Pharmaceutical Co., Ltd.
- Provider of Information About this Clinical Study
- Sponsor-Investigator: YongChan Lee, Professor – Severance Hospital
- Overall Official(s)
- Yong Chan Lee, MD, PhD, Principal Investigator, Severance Hospital, Yonsei University Health System
- Seong Woo Jeon, MD, PhD, Principal Investigator, Kyungpook National University Medical Center
- Su Jin Hong, MD, PhD, Principal Investigator, Soonchunhyang University Buchen Hospital
- Kyung Ho Song, MD, Master, Principal Investigator, Konyang University Hospital
- Shiming Yang, MD, PhD, Principal Investigator, Xinqiao Hospital of Chongqing
Chai J, Jamal MM. Esophageal malignancy: a growing concern. World J Gastroenterol. 2012 Dec 7;18(45):6521-6. doi: 10.3748/wjg.v18.i45.6521.
Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006 Aug;101(8):1900-20; quiz 1943.
Peery AF, Dellon ES, Lund J, Crockett SD, McGowan CE, Bulsiewicz WJ, Gangarosa LM, Thiny MT, Stizenberg K, Morgan DR, Ringel Y, Kim HP, DiBonaventura MD, Carroll CF, Allen JK, Cook SF, Sandler RS, Kappelman MD, Shaheen NJ. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology. 2012 Nov;143(5):1179-1187.e3. doi: 10.1053/j.gastro.2012.08.002. Epub 2012 Aug 8.
Wong RK, Yeoh KG, Gwee KA, Tay HW, Ho KY. Validation of structured scoring using the LA classification for esophagitis and endoscopically suspected Barrett's esophagus in a tertiary Asian endoscopy center. J Gastroenterol Hepatol. 2009 Jan;24(1):103-6. doi: 10.1111/j.1440-1746.2008.05680.x. Epub 2008 Dec 1.
Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2005 May;54(5):710-7. Review.
Kang JY. Systematic review: geographical and ethnic differences in gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2004 Oct 1;20(7):705-17. Review.
Kim KM, Cho YK, Bae SJ, Kim DS, Shim KN, Kim JH, Jung SW, Kim N. Prevalence of gastroesophageal reflux disease in Korea and associated health-care utilization: a national population-based study. J Gastroenterol Hepatol. 2012 Apr;27(4):741-5. doi: 10.1111/j.1440-1746.2011.06921.x.
Song JH, Chung SJ, Lee JH, Kim YH, Chang DK, Son HJ, Kim JJ, Rhee JC, Rhee PL. Relationship between gastroesophageal reflux symptoms and dietary factors in Korea. J Neurogastroenterol Motil. 2011 Jan;17(1):54-60. doi: 10.5056/jnm.2011.17.1.54. Epub 2011 Jan 26.
Lee SJ, Song CW, Jeen YT, Chun HJ, Lee HS, Um SH, Lee SW, Choi JH, Kim CD, Ryu HS, Hyun JH. Prevalence of endoscopic reflux esophagitis among Koreans. J Gastroenterol Hepatol. 2001 Apr;16(4):373-6.
Hwang JK, Kim J, Hong SG, Jung SJ, Joo MK, Lee BJ, Park JJ, Kim JS, Bak YT. [A prospective multicenter study on the prevalence and symptoms of erosive reflux esophagitis in secondary and tertiary hospitals in Korea]. Korean J Gastroenterol. 2009 May;53(5):283-91. Korean.
Kim BJ, Cheon WS, Oh HC, Kim JW, Park JD, Kim JG. Prevalence and risk factor of erosive esophagitis observed in Korean National Cancer Screening Program. J Korean Med Sci. 2011 May;26(5):642-6. doi: 10.3346/jkms.2011.26.5.642. Epub 2011 Apr 21.
Li YM, Du J, Zhang H, Yu CH. Epidemiological investigation in outpatients with symptomatic gastroesophageal reflux from the Department of Medicine in Zhejiang Province, east China. J Gastroenterol Hepatol. 2008 Feb;23(2):283-9. Epub 2007 Jul 20.
Shaw MJ, Crawley JA. Improving health-related quality of life in gastro-oesophageal reflux disease. Drugs. 2003;63(21):2307-16. Review.
Kovacs TO, Freston JW, Haber MM, Atkinson S, Hunt B, Peura DA. Long-term quality of life improvement in subjects with healed erosive esophagitis: treatment with lansoprazole. Dig Dis Sci. 2010 May;55(5):1325-36. doi: 10.1007/s10620-009-0871-8. Epub 2009 Jul 7.
Howden CW, Chey WD. Gastroesophageal reflux disease. J Fam Pract. 2003 Mar;52(3):240-7. Review.
Lee JH, Cho YK, Jeon SW, Kim JH, Kim NY, Lee JS, Bak YT; Korean Society of Neurogastroenterology and Motility. [Guidelines for the treatment of gastroesophageal reflux disease]. Korean J Gastroenterol. 2011 Feb;57(2):57-66. Korean.
Kovacs TO, Freston JW, Haber MM, Hunt B, Atkinson S, Peura DA. Long-term efficacy of lansoprazole in preventing relapse of erosive reflux esophagitis. Dig Dis Sci. 2009 Aug;54(8):1693-701. doi: 10.1007/s10620-009-0769-5. Epub 2009 Mar 7.
Yoshida N, Kamada K, Tomatsuri N, Suzuki T, Takagi T, Ichikawa H, Yoshikawa T. Management of recurrence of symptoms of gastroesophageal reflux disease: synergistic effect of rebamipide with 15 mg lansoprazole. Dig Dis Sci. 2010 Dec;55(12):3393-8. doi: 10.1007/s10620-010-1166-9. Epub 2010 Mar 3.
Hatlebakk JG, Berstad A. Lansoprazole 15 and 30 mg daily in maintaining healing and symptom relief in patients with reflux oesophagitis. Aliment Pharmacol Ther. 1997 Apr;11(2):365-72.
Lancaster GA, Dodd S, Williamson PR. Design and analysis of pilot studies: recommendations for good practice. J Eval Clin Pract. 2004 May;10(2):307-12.
Hongo M. Minimal changes in reflux esophagitis: red ones and white ones. J Gastroenterol. 2006 Feb;41(2):95-9. Review.
Kusano M, Ino K, Yamada T, Kawamura O, Toki M, Ohwada T, Kikuchi K, Shirota T, Kimura M, Miyazaki M, Nakamura K, Igarashi S, Tomizawa M, Tamura T, Sekiguchi T, Mori M. Interobserver and intraobserver variation in endoscopic assessment of GERD using the "Los Angeles" classification. Gastrointest Endosc. 1999 Jun;49(6):700-4.
Fiocca R, Mastracci L, Milione M, Parente P, Savarino V; Gruppo Italiano Patologi Apparato Digerente (GIPAD); Società Italiana di Anatomia Patologica e Citopatologia Diagnostica/International Academy of Pathology, Italian division (SIAPEC/IAP). Microscopic esophagitis and Barrett's esophagus: the histology report. Dig Liver Dis. 2011 Mar;43 Suppl 4:S319-30. doi: 10.1016/S1590-8658(11)60588-4.
Citations Reporting on Results
Holzheimer RG, Mannick JA, editors. Surgical Treatment: Evidence-Based and Problem-Oriented. Munich: Zuckschwerdt; 2001.
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.